Changes in Regional Cerebral Perfusion after Nicergoline Treatment in Early Alzheimer’s Disease: A Pilot Study

키워드

참고문헌 (57)

1. Scarpini E, "Treatment of Alzheimer’s dis-ease: current status and new perspectives", Lancet Neurol, 2, pp.539~547 (2003)
2. Gorelick PB, "Risk factors for vascular dementia and Alzheimer disease", Stroke, 35(11), pp.2620~2622 (2004)
3. Skoog I, "Vascular factors and Alzheimer disease", Alzheimer Dis Assoc Disord, 13(Suppl 3), pp.S106~S114 (1999)
4. Winblad B, "Nicergoline in dementia: a review of its pharmacological properties and therapeutic potential", CNS Drugs, 14, pp.267~287 (2000)
5. Bracco L, "Six-month, multicentre, doubleblind trial of nicergoline in the treatment of mild to moderate AD and its 12-month follow-up", Neurosci Lett, 552, pp.18~ (1999)
6. Crook TH, "Nicergoline in the treatment of probable Alzheimer’s disease. Preliminary results of a double-blind, randomized, placebo-controlled study", J Neurol Sci, 150, pp.S18~ (1997)
7. Winblad B, "Nicergoline in the treatment of mild- to- moderate Alzheimer’s disease", Clin Drug Investig, 21, pp.621~632 (2001)
8. Arrigo A, "A double-blind, placebo-controlled, crossover trial with nicergoline in patients with senile dementia", Int J Clin Pharmacol Res, 2(4), pp.33~41 (1982)
9. Battaglia A, "Nicergoline in mild to moderate dementia. A multicenter, double-blind, placebo-controlled study", J Am Geriatr Soc, 37, pp.295~302 (1989)
10. Nappi G, "Long-term nicergoline treatment of mild to moderate senile dementia:results of a multicentre, double-blind, placebo-controlled study", Clin Drug Investig, 13, pp.308~316 (1997)
11. Saletu B, "Nicergoline in senile dementia of Alzheimer type and multiinfarct dementia: a double-blind, placebo-controlled, clinical and EEG", ERP mapping study, 1995, pp.117, 385~395
12. Winblad B, "Therapeutic use of nicergoline", Clin Drug Investig, 28, pp.533~552 (2008)
13. Carfagna N, "Modulation of hippocampal ACh release by chronic nicergoline treatment in freely moving young and aged rats", Neurosci Lett, 197, pp.195~198 (1995)
14. McArthur RA, "Effects of nicergoline on age-related decrements in radial maze performance and acetylcholine levels", Brain Res Bull, 43, pp.305~311 (1997)
15. Ogawa N, "Cholinergic deficits in aged rat brain are corrected with nicergoline", Arch Gerontol Geriatr, 16, pp.103~110 (1993)
16. Moretti A, "Effect of ergolines on neurotransmitter systems in the rat brain", Arch Int Pharmacodyn Ther, 294, pp.33~45 (1988)
17. Le Poncin-Lafitte M, "Simultaneous study of haemodynamic, metabolic and behavioural sequelae in a model of cerebral ischaemia in aged rats: effects of nicergoline", Gerontology, 30, pp.109~119 (1984)
18. Miccheli A, "Glucose entry in neuronal and astrocytic intermediary metabolism of aged rats. A study of the effects of nicergoline treatment by 13C NMR spectroscopy", Brain Res, 966, pp.116~125 (2003)
19. Caraci F, "Nicergoline, a drug used for age-dependent cognitive impairment, protects cultured neurons against beta-amyloid toxicity", Brain Res, 1047, pp.30~37 (2005)
20. Mizuno T, "Protective effects of nicergoline against neuronal cell death induced by activated microglia and astrocytes", Brain Res, 1066, pp.78~85 (2005)
21. Sortino MA, "Neuroprotective effects of nicergoline in immortalized neurons", Eur J Pharmacol, 368, pp.285~290 (1999)
22. Caputi A, "Nicergoline and its metabolite induce translocation of PKC isoforms in selective rat brain areas", Neurosci Res Commun, 23, pp.159~167 (1998)
23. Carfagna N, "Modulation of phosphoinositide turnover by chronic nicergoline in rat brain", Neurosci Lett, 209, pp.189~192 (1996)
24. Cedazo-Minguez A, "Nicergoline stimulates protein kinase C mediated alpha-secretase processing of the amyloid precursor protein in cultured human neuroblastoma SH-SY5Y cells", Neurochem Int, 35, pp.307~315 (1999)
25. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR), "American Psychiatric Association", American Psychiatric Association, ~ (2000)
26. McKhann G, "Clinical diagnosis of Alzheimer’s disease: report of the NINCDSADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease", Neurology, 34, pp.939~944 (1984)
27. Kang Y, "A validity study on the Korean Mini-Mental State Examination (K-MMSE) in dementia patients", J Korean Neurol Assoc, 15, pp.300~308 (1997)
28. Morris JC, "The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer’s disease", Neurology, 39, pp.1159~1165 (1989)
29. 최성혜, "한국판 Global Deterioration Scale의 타당도", 대한신경과학회지, 20(6), pp.612~617 (2002), 대한신경과학회
30. Wade DT, "The Barthel ADL Index: a standard measure of physical disability?", Int Disabil Stud, 10, pp.64~67 (1988)
31. 강수진, "한국판 Instrumental Activities of Dalily Living의 타당도와 신뢰도", 대한신경과학회지, 20(1), pp.8~14 (2002), 대한신경과학회
32. Jung IK, "A reliability and validity study of geriatric depression scale", J Korean Neuropsychiatr Assoc, 36, pp.103~112 (1997)
33. Tzourio-Mazoyer N, "Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain", Neuroimage, 15, pp.273~289 (2002)
34. Pickut BA, "Validation of the cerebellum as a reference region for SPECT quantification in patients suffering from dementia of the Alzheimer type", Psychiatry Res, 90, pp.103~112 (1999)
35. Soonawala D, "Statistical parametric mapping of (99m)Tc-HMPAO-SPECT images for the diagnosis of Alzheimer’s disease: normalizing to cerebellar tracer uptake", Neuroimage, 17, pp.1193~1202 (2002)
36. Kogure D, "Longitudinal evaluation of early Alzheimer’s disease using brain perfusion SPECT", J Nucl Med, 41, pp.1155~1162 (2000)
37. Benoit M, "One-year longitudinal evaluation of neuropsychiatric symptoms in Alzheimer’s disease. The REAL.FR Study", J Nutr Health Aging, 9, pp.95~99 (2005)
38. Burns A, "Progression of cognitive impairment in Alzheimer’s disease", J Am Geriatr Soc, 39, pp.39~45 (1991)
39. Masdeu JC, "Neuroimaging as a marker of the onset and progression of Alzheimer’s disease", J Neurol Sci, 236, pp.55~64 (2005)
40. Scahill RI, "Mapping the evolution of regional atrophy in Alzheimer’s disease: unbiased analysis of fluid-registered serial MRI", Proc Natl Acad Sci U S A, 99, pp.4703~4707 (2002)
41. Coffey CE, "Quantitative cerebral anatomy of the aging human brain: a cross-sectional study using magnetic resonance imaging", Neurology, 42(3), pp.527~536 (1992)
42. Fox NC, "Imaging cerebral atrophy: normal ageing to Alzheimer’s disease", Lancet, 363, pp.392~394 (2004)
43. Raz N, "Selective aging of the human cerebral cortex observed in vivo: differential vulnerability of the prefrontal gray matter", Cereb Cortex, 7, pp.268~282 (1997)
44. Resnick SM, "Longitudinal magnetic resonance imaging studies of older adults: a shrinking brain", J Neurosci, 23, pp.3295~3301 (2003)
45. Drzezga A, "Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer’s disease:a PET follow-up study", Eur J Nucl Med Mol Imaging, 30, pp.1104~1113 (2003)
46. Encinas M, "Regional cerebral blood flow assessed with 99mTc-ECD SPET as a marker of progression of mild cognitive impairment to Alzheimer’s disease", Eur J Nucl Med Mol Imaging, 30, pp.1473~1480 (2003)
47. Chase TN, "Regional cortical dysfunction in Alzheimer’s disease as determined by positron emission tomography", Ann Neurol, 15, pp.S170~S174 (1984)
48. Friedland RP, "Alzheimer’s disease:anterior-posterior and lateral hemispheric alterations in cortical glucose utilization", Neurosci Lett, 53, pp.235~240 (1985)
49. Metter EJ, "Cerebral metabolic relationships for selected brain regions in Alzheimer’s, Huntington’s, and Parkinson’s diseases", J Cereb Blood Flow Metab, 4, pp.500~506 (1984)
50. Perani D, "Technetium-99m HM-PAO-SPECT study of regional cerebral perfusion in early Alzheimer’s disease", J Nucl Med, 29, pp.1507~1514 (1988)
51. du Boisgueheneuc F, "Functions of the left superior frontal gyrus in humans:a lesion study", Brain, 129, pp.3315~3328 (2006)
52. Albers MW, "At the interface of sensory and motor dysfunctions and Alzheimer’s disease", Alzheimers Dement, 11, pp.70~98 (2015)
53. Kimura N, "Evaluation of the regional cerebral blood flow changes during long-term donepezil therapy in patients with Alzheimer’s disease using 3DSRT", J Neuroimaging, 22, pp.299~304 (2012)
54. Nobili F, "Brain perfusion follow-up in Alzheimer’s patients during treatment with acetylcholinesterase inhibitors", J Nucl Med, 43, pp.983~990 (2002)
55. Ushuijima Y, "Regional cerebral blood flow in Alzheimer’s disease: comparison between short and long-term donepezil therapy", Ann Nucl Med, 20, pp.425~429 (2006)
56. Shimizu S, "SPECT followup study of cerebral blood flow changes during Donepezil therapy in patients with Alzheimer’s disease", J Neuroimaging, 16, pp.16~23 (2006)
57. Shimizu S, "Differential effects of acetylcholinesterase inhibitors on clinical responses and cerebral blood flow changes in patients with Alzheimer’s disease: a 12-month, randomized, and open-label trial", Dement Geriatr Cogn Dis Extra, 5, pp.135~146 (2015)

관련 논문AI추천